Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of IMCY-0098 in T1D
NCT04190693Phase 1Completed
- Sponsor
- Imcyse
- Start
- Feb 2019
- Primary completion
- Oct 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Peptides
- Countries
- 7
01
Overview
Phase 1, double-blind trial of imcy-0098 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Imcyse. Primary endpoints: Adverse Events at 24 weeks and Serious Adverse Events at 24 weeks. Started Feb 2019; status: completed.
02
Drugs
imcy-0098
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04190693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04190693.